Close Many team members at Unicorn Nest are Ukrainians affected by Russian aggression. We do our best to solve any issues and answer your questions in the shortest possible time frames but some delays are possible.

OrbiMed

Investor type Private Equity Firm

Overview

Unlock datapoints

Portfolio analytics

Team

Investments

News & Media

Add fund to favorites
info
Save this fund for later to form your own custom list of funds
This summary is composed by our algorithm based on the analysis of the deals. If you think that some of this information is not accurate, please let us know about it and provide any supporting evidences if possible. Such cases will be analyzed by our ML-algorithm and implemented in our database, which will improve this summary.
Total investments 576
Average round size
info
The average size of a deal this fund participated in
$65M
Portfolio companies 364
Rounds per year 17.45
Lead investments 136
Follow on index
info
How often the fund supports its portfolio startups at next rounds
0.37
Exits 181
Key employees 15
Stages of investment
Early Stage Venture
Late Stage Venture
Private Equity

Areas of investment

  • Biotechnology
  • Health Care
  • Pharmaceutical
  • Medical
  • Therapeutics
Summary

In 1989 was created OrbiMed, which is appeared as VC. The venture was found in North America in United States. The leading representative office of defined VC is situated in the New York.

Besides them, we counted 15 critical employees of this fund in our database.

The typical case for the fund is to invest in rounds with 5-6 participants. Despite the OrbiMed, startups are often financed by New Enterprise Associates, Kearny Venture Partners, Sequoia Capital. The meaningful sponsors for the fund in investment in the same round are Deerfield, Alta Partners, Topspin Partners. In the next rounds fund is usually obtained by Versant Ventures, Venrock, OUP (Osage University Partners).

Among the most popular portfolio startups of the fund, we may highlight Loxo Oncology, Receptos, Avanir Pharmaceuticals. Among the most popular fund investment industries, there are Biotechnology, Clinical Trials. Besides, a startup needs to be aged 6-10 years to get the investment from the fund. The fund has exact preference in some founders of portfolio startups. In case when startup counts 5+ of the founder, the chance for it to get the investment is meager. For fund there is a match between the location of its establishment and the land of its numerous investments - United States.

Speaking about the real fund results, this VC is 22 percentage points more often commits exit comparing to other organizations. The important activity for fund was in 2017. Despite it in 2019 the fund had an activity. The common things for fund are deals in the range of 10 - 50 millions dollars. The typical startup value when the investment from OrbiMed is 100-500 millions dollars. Opposing the other organizations, this OrbiMed works on 6 percentage points more the average amount of lead investments. The top amount of exits for fund were in 2015. The fund is generally included in 13-24 deals every year.

Read more

Related Funds

Funds investing in previous rounds
These funds often invest in the rounds preceeding the rounds of OrbiMed:
Typical Co-investors
OrbiMed is more likely to invest in rounds together with the following funds:
Funds investing in following rounds
These funds have a tendency to invest in the following rounds after OrbiMed:

Funds with similar focus

Funds from United States
Funds with similar focus located in United States:
Funds with the same geo focus
Funds with similar geography of portfolio companies:
Funds doing lead investments
Funds with similar focus acting as lead investors:

Notable deals

CompanyIndustryRound SizeDateInvestorsLocation

Capstan Therapeutics

Biotechnology
Health Care
Therapeutics
$102M14 Sep 2022 San Diego, California, United States

ACELYRIN

Biopharma
Biotechnology
Health Care
$300M13 Sep 2022 Los Angeles, California, United States

Adaptive Biotechnologies

Biotechnology
Health Care
Therapeutics
$125M12 Sep 2022 Seattle, Washington, United States

Disc Medicine

Biotechnology
Health Care
Medical
$53M10 Aug 2022 Cambridge, Massachusetts, United States

Delfi Diagnostics

Biotechnology
Health Care
Health Diagnostics
$225M18 Jul 2022 Baltimore, Maryland, United States

LifeWell

Health Care
Health Diagnostics
$80M11 Jul 2022 -

X4 Pharmaceuticals

Biotechnology
Clinical Trials
Health Care
Pharmaceutical
Therapeutics
$55M30 Jun 2022 Cambridge, Massachusetts, United States

MiroBio

Biotechnology
Life Science
$109M29 Jun 2022 Oxford, England, United Kingdom

Aerin Medical

Biotechnology
Health Care
Medical Device
$60M16 Jun 2022 Sunnyvale, California, United States
News
ReCode Therapeutics Raises Oversubscribed Series B Financing Round of $80 Million

– ReCode Therapeutics announced the closing of an $80m Series B financing round co-led by Pfizer Ventures and EcoR1 Capital.
– The round was led by Pfizer Ventures and EcoR1 Capital.
– New investors include Sanofi Ventures, funds managed by Tekla Capital Management, Superstring Capital and NS Investment.
– Existing investors who participated included OrbiMed, Vida Ventures, MPM Capital, Colt Ventures, Hunt Technology Ventures, and Osage University Partners.

Garuda Therapeutics Raises $72M in Series A Financing

– Garuda Therapeutics from Cambridge develops off-the-shelf, durable blood stem cell therapies.
– Series A funding of $72m brings company valuation to more than $1b.
– The round was led by Aisling Capital, Northpond Ventures and Orbimed, supported by Cormorant Asset Management, Ridgeback Capital Investments, Monashee Investment Management, Sectoral Asset Management, National Resilience, Inc. (Resilience), Mass General Brigham Ventures, among others.

Review

  • No reviews are submitted yet.
Do you want more?
We provide dozens of additional datapoints about this fund.
Sign up and get access to full fund profile and advanced analysis.
Full team
Industries heatmap
Stages heatmap
Georgaphy breakdown
Coinvestors
Portfolio analysis
Performance indexes
Latest highlights
Unlock all data
Do you represent OrbiMed?
Get access to manage this page
Get in touch
Found incorrect info? Let us know!

Wait!
You can raise money with us faster

Get matched with relevant funds

Find decision makers data

Connect with investors by email

Remind me later
...and save more than 200 hours*
*-Our recommendation and outreach system saves up to 200 hours of founder time on fundraising for seed and series A+ startups
We use LinkedIn only to verify your account. We don't import or message your contacts, nor post on your behalf.
By creating an account, you agree to our Terms of Service and Privacy Policy.
Crunchbase icon

Content report

The following text will be sent to our editors: